Astellas announces Caduet agreement with Pfizer
26 August 2009 00:00 in Pharmaceutical Company Product News
Astellas and Pfizer have entered into an agreement which will see the two firms collaborate to co-promote Caduet Combination Tablets.
The tablets - which are made up of a hypertension treatment and a hypercholesterolemia treatment (amlodipine besylate and atorvastatin calcium), will be manufactured and sold by Pfizer.
Astellas will contribute to the promotional efforts and will also receive a fee as part of the contract, which expires in July 2016.
Caduet Combination Tablets constitute the hypertension treatment Norvasc Tablets and Lipitor Tablets, which are used for the management of hypercholesterolemia. They have received approval in over 70 countries.
Earlier this month, Astellas agreed to collaborate with to conduct a late-stage clinical trial for the irregular heartbeat treatment Kynapid for, which has been delayed twice already.
Employing 14,000 people worldwide, Astellas' global sales reached 972.6 billion yen (6.327 billion pounds) in 2008.
Other news stories from 26/08/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency